Increase in conjugated linoleic acid content and improvement in microbial and physicochemical properties of a novel kefir stored at refrigerated temperature using complementary probiotics and prebiotic

Conjugated linoleic acid in cheese: A review of the factors affecting its presence

Several health benefits of conjugated linoleic acid (CLA) have been documented. The present work is aimed to review data on the various factors affecting the CLA content in cheese of studies accomplished in the last decade and also indicating the factors that increase the CLA levels. The CLA content in cheese depends on CLA levels present in milk, since the lipids with the CLA are transferred from milk into the cheese. Feed types rich in α-linolenic and linoleic acids such as pasture grass, plant oils, cereals rich in oil, or fish oils can affect the CLA level in milk. In contrast to findings of previous reviews made in previous decade, which stated that the CLA levels in cheese were stable during ripening time, the present review reveals that certain lactic acid bacteria, that is, probiotic Lactiplantibacillus plantarum, Lactobacillus acidophilus, or Lacticaseibacillus casei, as well as Bifidobacterium lactis can increase the CLA levels in cheese by converting linoleic acid during ripening time. These bacteria starters increased the CLA levels by 1.19, 1.6, and 6.6 times as much as the control in Ovine model, Miniature, and Cheddar cheese, respectively. Lipid oxidation due to factors like fluorescent light or aerobic conditions can decrease the CLA levels during storage.

Effect of nanoemulsified and encapsulated Planiliza abu protein on fortified yogurt

Fortified dairy products such as yogurt have attracted a lot of attention due to the increasing concern for public health. This study aimed to determine the effects of nanoemulsified and a microencapsulated protein hydrolysate obtained from Planiliza abu on some of the properties of yogurt. The physicochemical, rheological, microbiological, and sensory evaluation of the fortified yogurt samples stored at 4°C were assessed during 21 days. The fish protein hydrolysates (FPHs) < or >10 kDa protein were used. The amino acid profile of Planiliza abu was glutamic acid (78.99%), aspartic acid (59.53%), and lysine (53.54%). No significant change was observed in titratable acidity (TA) and pH of supplemented yogurts during refrigeration. The highest survival level of lactic acid bacteria (LAB), water-holding capacity (WHC), and viscosity and the lowest syneresis were observed in fortified samples with FPH <10 kDa. The highest ferric reducing antioxidant power (FRAP) was achieved in yogurt fortified with nanoemulsion FPH < 10 kDa (NEh10a, 0.41 mg/g). The results showed that fortified yogurt with FPH, particularly less than 10 kDa, is among the desirable functional food with appropriate gel network and consistency as well as better taste and mouth feel, and higher overall acceptance.

Potential strategies to enhance conjugated linoleic acid content of milk and dairy products: A review

Conjugated linoleic acid (CLA) is a general term for all the geometric and positional isomers of linoleic acid. The cis-9, trans-11 CLA and trans-10 cis-12 CLA are considered to be the most abundant and essential isomers associated with health benefits. Though milk and dairy products are considered to be the major sources of CLA, the CLA content found in regular milk and dairy products is relatively low for effective health benefits in human beings. Thus, for effective health benefits, increasing the concentration of CLA in milk and dairy products is beneficial. Dietary supplementation with PUFA-rich lipid sources such as oilseeds and/or vegetable oils, fish meal, fish oil and microalgae and grass-based feeding can enhance the content of CLA in milk and dairy products. Application of CLA-producing bacterial strains during the fermentation process and ripening/storage are considered as potential strategies for enhancing the CLA content of fermented dairy products. Alternatively, the CLA content of milk and dairy products can be improved using genetic factor. In this paper, the latest scientific studies regarding CLA enrichment in milk and dairy products are reviewed, giving an overview of the effectiveness of the different CLA enrichment strategies and their combinations.

Manipulation of the diet-microbiota-brain axis in Alzheimer's disease

Several studies investigating the pathogenesis of Alzheimer's disease have identified various interdependent constituents contributing to the exacerbation of the disease, including Aβ plaque formation, tau protein hyperphosphorylation, neurofibrillary tangle accumulation, glial inflammation, and the eventual loss of proper neural plasticity. Recently, using various models and human patients, another key factor has been established as an influential determinant in brain homeostasis: the gut-brain axis. The implications of a rapidly aging population and the absence of a definitive cure for Alzheimer's disease have prompted a search for non-pharmaceutical tools, of which gut-modulatory therapies targeting the gut-brain axis have shown promise. Yet multiple recent studies examining changes in human gut flora in response to various probiotics and environmental factors are limited and difficult to generalize; whether the state of the gut microbiota in Alzheimer's disease is a cause of the disease, a result of the disease, or both through numerous feedback loops in the gut-brain axis, remains unclear. However, preliminary findings of longitudinal studies conducted over the past decades have highlighted dietary interventions, especially Mediterranean diets, as preventative measures for Alzheimer's disease by reversing neuroinflammation, modifying the intestinal and blood-brain barrier (BBB), and addressing gut dysbiosis. Conversely, the consumption of Western diets intensifies the progression of Alzheimer's disease through genetic alterations, impaired barrier function, and chronic inflammation. This review aims to support the growing body of experimental and clinical data highlighting specific probiotic strains and particular dietary components in preventing Alzheimer's disease via the gut-brain axis.

The potential of probiotics in the amelioration of hyperuricemia

Hyperuricemia is a common disease caused by metabolic disorders or the excessive intake of high-purine foods. Persistent hyperuricemia in extreme cases induces gout, and asymptomatic hyperuricemia is probably linked to other metabolic diseases, such as hypertension. The typical damage caused by asymptomatic hyperuricemia includes inflammation, oxidative stress and gut dysbiosis. Probiotics have broad potential applications as food additives, not as drug therapies, in the amelioration of hyperuricemia. In this review, we describe novel methods for potential hyperuricemia amelioration with probiotics. The pathways through which probiotics may ameliorate hyperuricemia are discussed, including the decrease in uric acid production through purine assimilation and XOD (xanthine oxidase) inhibition as well as enhanced excretion of uric acid production by promoting ABCG2 (ATP binding cassette subfamily G member 2) activity, respectively. Three possible probiotic-related therapeutic pathways for alleviating the syndrome of hyperuricemia are also summarized. The first mechanism is to alleviate the oxidation and inflammation induced by hyperuricemia through the inhibition of NLRP3 inflammasome, the second is to restore damaged intestinal epithelium barriers and prevent gut microbiota dysbiosis, and the third is to enhance the innate immune system by increasing the secretion of immunoglobulin A (sIgA) to resist the stimulus by hyperuricemia. We propose that future research should focus on superior strain resource isolation and insight into the cause-effect mechanisms of probiotics for hyperuricemia amelioration. The safety and effects of the application of probiotics in clinical use also need verification.